Biohaven Pharmaceuticals, Inc: Commercial-stage, focused on neurological & neuropsychiatric diseases; CGRP receptor antagonist, glutamate modulation, and MPO platforms. NURTEC® ODT approved 1Q20 (acute treatment of migraine); $17.7m 3Q20 revenues (80% increase over 2Q20). NURTEC ODT preventive treatment of migraine sNDA filing accepted by FDA; PDUFA goal date in 2Q21. 4Q21 exp. Ph 3 MSA readout. Cash - $552m (9/30/20)
US - New England
Central Nervous System, Rare Disease
215 Church Street
New Haven, CT 06510
New Haven, CT 06510
Company Participants at Solebury Trout Virtual Management Access Event 2021
Biohaven Pharmaceuticals, Inc, Chief Scientific OFficer
Dr. Conway has 28 years of research experience examining the biology of pain mechanisms, including 17 years of pharma experience in drug discovery and development in positions of increasing responsibility at Bristol-Myers Squibb Company (BMS). Dr. Conway led BMS’s biology program efforts on the CGRP receptor antagonist for over 10 years and was part of the development team advancing rimegepant into the clinic. He designed a series of experiments that established a novel life-sparing recovery assay in marmosets enabling ongoing reuse and savings while delivering in vivo efficacy measures for the CGRP program, and was recognized for this effort by the first ever BMS Animal Welfare Award. Dr. Conway’s extensive experience in the field of pain research has resulted in being an inventor on three granted U.S. patents for the treatment of pain. Dr. Conway was intimately involved in Neuroscience programs advancing biologic and small molecule assets, and held pivotal roles driving drug discovery efforts in pain. Dr. Conway’s career at BMS was distinguished by a successful record as a flexible leader of high performing teams in both Discovery Biology and Lead Profililg, including leading the in vitro profiling of all BMS discovery assets for adsorption, distribution, metabolism, excretion and toxicology (ADMET) properties. Dr. Conway is a tech-savvy researcher with a long track-record of successfully bringing advances in technology and data science into the lab to accelerate high-quality decision making in drug discovery programs. Prior to his time at BMS, Dr. Conway carried out postgraduate studies in the Anesthesiology Research Laboratory under the guidance of Dr Tony Yaksh at the University of California San Diego where he studied the spinal pharmacology of pain mechanisms and showed that spinal COX-2, but not COX-1, is an important contributor to the acute antihyperalgesic effects of NSAIDS (Yaksh, Dirig, Conway et al., 2001). Dr. Conway received his doctoral training in the Laboratory of Psychopharmacology under the tutelage of Dr. Loy Lytle where he earned a Ph.D. in Neuroscience from the University of California Santa Barbara and was first to systematically characterize maturational changes in the development of nociceptive (pain) mechanisms (Conway et al., 1998).
Biohaven Pharmaceuticals, Inc, Chief Operating Officer
Cliff is a 27-year veteran of the Pharmaceutical industry with a broad drug development experience and a track record of optimizing organizations and capabilities. Prior to joining Biohaven, Cliff was the Development Lead for Genetically Defined Diseases at Bristol-Myers Squibb Company (BMS). In this role he led the teams which developed innovative strategies and executed on two novel programs in neuromuscular and neurodegenerative diseases. In addition to these disease areas, Cliff has in-depth experience in all stages of program advancement from discovery to launch in diverse disease areas including virology, oncology, immunology, cardiovascular and neuroscience. This includes key leadership roles for the development and launch of Reyataz® and Sprycel®. At BMS, he also served as Head of Biologics Strategy and Operations with a key role in optimizing the company’s biologics development and manufacturing capabilities. As the Head of Strategic Operations at Adnexus Therapeutics, Cliff oversaw the organizational optimization and strategic integration. Through his career, Cliff has held multiple positions in Discovery, Clinical Development and leadership roles in Project Planning and Management. Cliff is currently serving as a member of the TREAT-NMD Advisory Committee for Therapeutics (TACT), ImagingDMD scientific advisory board and consults for Project Parent Muscular Dystrophy (PPMD). Cliff holds a Master of Science degree in Medical Microbiology from Creighton University School of Medicine and a Bachelor of Science degree from South Dakota State University.
Biohaven Pharmaceuticals, Inc, Chief Financial Officer
Mr. Engelhart brings to Biohaven 30 years of finance experience including over 17 years within the pharmaceutical industry at Alexion Pharmaceuticals, Bristol-Myers Squibb and Schering-Plough. He joins Biohaven from Alexion Pharmaceuticals where he was Executive Director, Finance of the North America and Latin America Regions, providing financial leadership, strategy, and planning to the regions including two simultaneous OrphanDrug Launches in the US. Previously, Mr. Engelhart’s finance roles have spanned strategic planning and analysis at the Corporate, Commercial, and R&D levels, business restructuring and M&A, two international assignments, and a strong foundation in accounting and internal controls. He began his career at Coopers and Lybrand. Mr. Engelhart is a graduate of Villanova University’s School of Business where he earned a Bachelor of Science degree in Accountancy and is a Certified Public Accountant.
Biohaven Pharmaceuticals, Inc, Vice President, Finance
Vlad Coric, M.D.
Biohaven Pharmaceuticals, Inc, Chief Executive Officer
Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology
Top 10 Holders of Biohaven Pharmaceutical Holding Company Ltd.
|Institution||OS (%)||Position||Mkt Val ($MM)||Source||Filing Date|
|Capital Research & Management Co. (Global Investors)||10.37||6,072,149||431.79||Funds||3/31/21|
|Capital Research & Management Co. (International Investors)||9.11||5,330,978||379.09||13F||12/31/20|
|Capital Research & Management Co. (World Investors)||7.94||4,649,448||330.62||13F||12/31/20|
|Marshall Wace LLP||4.37||2,556,552||181.80||13F||12/31/20|
|1919 Investment Counsel LLC||4.34||2,541,823||180.75||13F||12/31/20|
|Oracle Investment Management, Inc.||3.67||2,148,271||152.76||13F||12/31/20|
|RP Management LLC||3.61||2,111,111||150.12||13F||12/31/20|
|Eventide Asset Management LLC||3.05||1,783,761||126.84||13F||12/31/20|
|State Street Corp.||2.86||1,671,949||118.89||13F||12/31/20|
|BlackRock Fund Advisors||2.83||1,656,048||117.76||13F||12/31/20|
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...